Abstract 470TiP
Background
Palmar-plantar erythrodysesthesia (PPE) is a typical adverse cutaneous reaction associated with capecitabine. PPE can be painful and debilitating, interfering with patients’ daily functions and impacting their quality of life. There is no effective treatment for PPE except dose modification and treatment interruption. Besides that, urea cream has been proven to be effective in preventing the occurrence and worsening of PPE in several studies and it is used as part of the standard of care for PPE. Vitamin E possess anti-inflammatory and antioxidant properties and has been used to treat a variety of skin conditions. Although oral vitamin E has been shown to be effective in treating PPE in small observational studies, there is no study done on the use of topical vitamin E in PPE management. We also noted patient with PPE typically starts with dry skin. Therefore, in the current study, we aim to determine the effect of moisturising cream with or without palm-oil-derived vitamin E concentrate in addition to urea cream versus urea cream alone in patients receiving capecitabine-based treatment and developed NCI-CTCAE grade 1 PPE.
Trial design
This is a single-centred, three-arm, randomised controlled trial in patients from Sarawak General Hospital, Malaysia. In this study, 90 patients will be enrolled and randomised to three study arms (1:1:1). Both patients and study team will be blinded to the investigational moisturising cream assignment i.e. double-blind. However, the group that uses urea-based cream only will be open-label. The patients will need to use the cream(s) twice a day daily for nine to eighteen weeks or equivalent to three to six treatment cycles of the capecitabine-based regime. The primary endpoint is resolution of PPE (grade 1 to 0). The secondary endpoints are prevention of worsening of PPE (grade 1 to 2/3), time-to-PPE resolution/worsening, Dermatology Life Quality Index, and pain score. We have currently recruited 20 out of 90 patients.
Clinical trial identification
NCT05939726.
Legal entity responsible for the study
The authors.
Funding
1. Avantsar Sdn Bhd 2. Ministry of Health Malaysia.
Disclosure
K.H. Yuen: Financial Interests, Institutional, Full or part-time Employment: Sarawak Palm Oil Berhad. All other authors have declared no conflicts of interest.
Resources from the same session
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract